Resolution of donor non-alcoholic fatty liver disease following liver transplantation

被引:8
|
作者
Posner, Andrew D. [1 ]
Sultan, Samuel T. [2 ]
Zaghloul, Norann A. [1 ]
Twaddell, William S. [1 ]
Bruno, David A. [2 ]
Hanish, Steven I. [2 ]
Hutson, William R. [1 ]
Hebert, Laci [2 ]
Barth, Rolf N. [2 ]
LaMattina, John C. [2 ]
机构
[1] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Div Transplantat, Baltimore, MD 21201 USA
关键词
biopsy; donors and donation: extended criteria; liver allograft function; dysfunction; SEVERELY STEATOTIC GRAFTS; BILIARY COMPLICATIONS; SURVIVAL; RISK; STEATOHEPATITIS; MACROSTEATOSIS; EPIDEMIOLOGY; RECIPIENT;
D O I
10.1111/ctr.13032
中图分类号
R61 [外科手术学];
学科分类号
摘要
IntroductionTransplant surgeons conventionally select against livers displaying high degrees (>30%) of macrosteatosis (MaS), out of concern for primary non-function or severe graft dysfunction. As such, there is relatively limited experience with such livers, and the natural history remains incompletely characterized. We present our experience of transplanted livers with high degrees of MaS and microsteatosis (MiS), with a focus on the histopathologic and clinical outcomes. MethodsTwenty-nine cases were identified with liver biopsies available from both the donor and the corresponding liver transplant recipient. Donor liver biopsies displayed either MaS or MiS 15%, while all recipients received postoperative liver biopsies for cause. ResultsThe mean donor MaS and MiS were 15.6% (range 0%-60%) and 41.3% (7.5%-97.5%), respectively. MaS decreased significantly from donor (M=15.6%) to recipient postoperative biopsies (M=0.86%), P<.001. Similarly, MiS decreased significantly from donor biopsies (M=41.3%) to recipient postoperative biopsies (M=1.8%), P<.001. At a median of 68days postoperatively (range 4-384), full resolution of MaS and MiS was observed in 27 of 29 recipients. ConclusionsHigh degrees of MaS and MiS in donor livers resolve in recipients following liver transplantation. Further insight into the mechanisms responsible for treating fatty liver diseases could translate into therapeutic targets.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [21] Approach to prevention of non-alcoholic fatty liver disease after liver transplantation
    Sharma, Praveen
    Arora, Anil
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 5
  • [22] Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity
    Townsend, S. A.
    Newsome, P. N.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (04) : 459 - 460
  • [23] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [24] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [25] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [26] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [27] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [28] Non-alcoholic fatty liver disease
    Carreras, MP
    Tortajada, GC
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
  • [29] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    BMC MEDICINE, 2017, 15
  • [30] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250